Pharmacology, Toxicology and Pharmaceutical Science
Activated Protein C Resistance
11%
Anticoagulant Agent
85%
Antivitamin K
50%
Apixaban
52%
Atrial Fibrillation
49%
Betrixaban
20%
Bleeding
46%
Blood Clotting Factor 10a Inhibitor
34%
Chronic Myeloid Leukemia
24%
Clinical Study
20%
Clotting Time
27%
Dabigatran
79%
Dabigatran Etexilate
57%
Daboia russellii
28%
Dasatinib
19%
Direct Oral Anticoagulant
77%
Diseases
19%
Drug
28%
Drug Concentration
11%
Drug Interaction
13%
Eculizumab
11%
Edoxaban
20%
Emergency
17%
Ensure
13%
Fibrinogen
11%
Heart Infarction
12%
Heparin
62%
Heparin Induced Thrombocytopenia
14%
Idarucizumab
13%
Low Molecular Weight Heparin
30%
Nilotinib
19%
Paroxysmal Nocturnal Hemoglobinuria
29%
Pathophysiology
11%
Pharmacodynamics
14%
Pharmacokinetics
12%
Ponatinib
19%
Prospective Study
19%
Protein Tyrosine Kinase Inhibitor
39%
Prothrombin
41%
Randomized Controlled Trial
11%
Reagent
44%
Rivaroxaban
91%
Survival
19%
Thrombin
41%
Thrombin Inhibitor
13%
Thromboembolism
33%
Thromboplastin
52%
Thrombosis
17%
Toxic Injury
15%
Viper Venom
29%
Medicine and Dentistry
Acute Leukemia
18%
Antibody
24%
Antibody Response
15%
Anticoagulation
17%
Antigen
17%
Apixaban
31%
Assay
100%
Assessment
32%
Betrixaban
21%
Blood
18%
Blood Clotting Factor 10a Inhibitor
15%
Blood Stasis
47%
Cell Function
19%
Cell Survival
19%
Cells
29%
Coagulation
43%
Combination Therapy
15%
COVID-19
49%
Diagnosis
40%
Direct Oral Anticoagulant
21%
Endothelial Cell
26%
Erythrocyte Concentrate
19%
Ex Vivo
16%
Fibrinogen
21%
Fibrinolysis
17%
Hemostat
21%
Heparin
42%
Heparin-Induced Thrombocytopenia
33%
In Vitro
26%
Infection
17%
Inpatient
30%
Laboratory
57%
Low Molecular Weight Heparin
16%
Membrane Microparticle
19%
Monitoring
28%
Neutrophil
19%
Paroxysmal Nocturnal Hemoglobinuria
19%
Patient
78%
Plasma
48%
Platelet
37%
Procoagulant
33%
Rivaroxaban
22%
Severe Acute Respiratory Syndrome Coronavirus 2
26%
Syndrome
19%
Therapeutic Procedure
41%
Thrombocytopenia
24%
Thromboplastin
22%
Thrombosis
50%
Tyrosine-Kinase Inhibitor
19%
Vaccine
26%
Biochemistry, Genetics and Molecular Biology
Acquired Disorder
9%
Activated Protein C Resistance
11%
All Cause Mortality
9%
Antibody
19%
Anticoagulation
25%
Antithrombin
18%
Association
9%
Blood Level
39%
Cell Function
9%
Cell Survival
9%
Coagulation
66%
Coronavirinae
11%
D-Dimer
26%
Disseminated Intravascular Coagulation
11%
Dose
14%
Electric Potential
18%
Fibrinogen
13%
Fibrinolysis
14%
Hemostasis
50%
Heparin
27%
Heparin-Induced Thrombocytopenia
9%
Hirudin
9%
Immune Response
9%
Impedance
11%
Laboratory Technique
9%
Myeloid
12%
Neutralizing Antibody
9%
Normal Human
9%
Partial Thromboplastin Time
29%
Platelet
19%
Ponatinib
11%
Prothrombin Time
35%
Quality Control
9%
Rivaroxaban
25%
Sample
47%
SARS Coronavirus
15%
Spherocytosis
9%
Tandem Mass Spectrometry
9%
Taxonomy
29%
Thrombin
88%
Thrombin Time
21%
Thrombocyte Activation
9%
Thrombocyte Aggregation
12%
Thrombocyte Function
9%
Thromboplastin
9%
Thrombotic Microangiopathy
9%
Time
43%
Tissue Factor Pathway Inhibitor
13%
Tyrosine Kinase Inhibitor
19%
Virus Load
9%